Consequently, blocking the Gal1‐mediated interaction between the tumor cells and TAMs further improved the efficacy of anti‐PD‐1 therapy, and Gal1 emerged as an attractive novel target for combination therapy of HCC patients. This evidence concerns the gene LGALS1 and neoplasm.